靶向丙型肝炎病毒生命周期的新型抗病毒治疗靶点  

Targeting the life cycle of hepatitis C virus for novel antiviral treatment

作　　者：钱汐晶[1] 朱勇喆[1] 戚中田[1] 

机构地区：[1]第二军医大学微生物学教研室上海市医学生物防护重点实验室,上海200433

出　　处：《中国病毒病杂志》2013年第2期149-154,共6页Chinese Journal of Viral Diseases

基　　金：国家自然科学基金(81273557)

摘　　要：丙型肝炎病毒(hepatitis C virus,HCV)是血液传播的球形包膜病毒,编码单正链RNA,是黄病毒科成员。目前,全世界约有1.7亿患者感染丙型肝炎病毒,每年有300万的新增感染病例,我国HCV感染者近4 000万。HCV慢性化程度高,约80%的急性感染者将发展为慢性肝脏疾病,其中又有约20%将最终进展到肝硬化。Hepatitis C is caused by hepatitis C virus （HCV） infection that leads to a large proportion of chro- nic infection and severe liver diseases including hepatic fibrosis, liver cirrhosis and hepatocellular carcino- ma. HCV infection has been a worldwide threat to human health. Because of the high specificity and low side effects, antiviral compounds targeting HCV life cycle have become one of the highlights in the development of artti-HCV drugs. This review systemically illustrates recent advances of new anti-HCV targets by directly tar- geting at the HCV life cycle.

关 键 词：丙型肝炎病毒 生命周期 抗病毒靶点 

分 类 号：R512.63[医药卫生—内科学]